Canakinumab Treatment Effective for Familial Mediterranean Fever
Canakinumab may be a useful first-line treatment for renal transplant recipients with familial Mediterranean fever (FMF), according to recent research. Immunosuppressive drugs can interact with colchicine, the standard first-line treatment for FMF, and increase the incidence of side effects, such as diarrhea and myopathy...
Source: The Rheumatologist - Category: Rheumatology Authors: Lara C. Pullen, PhD Tags: Conditions canakinumab Familial Mediterranean fever kidney transplant Renal transplantation Source Type: research
More News: Colchicine | Colcrys | Kidney Transplant | Kidney Transplantation | Rheumatology | Transplant Surgery | Transplants | Urology & Nephrology